通过CK2α介导的DUB3酸化促进了YAP1的稳定性和瘤功能
Lei Huang1, Yalei Wen2, Qin Guo3
1Department of General Surgery, Guangzhou Red Cross Hospital/State Key Laboratory of Bioactive Molecules and Druggability Assessment/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou, China.
Cell death & disease
|January 18, 2025
概括
氨酸激酶II (CK2) 通过DUB3.3调节YES相关蛋白1 (YAP1) 的稳定性. 抑制CK2会破坏YAP1的稳定,抑制癌症的进展,为卵巢和其他癌症提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 对相关蛋白1 (YAP1) 的上调驱动瘤进展和各种癌症的不良结果.
- 针对YAP1在治疗上具有挑战性,因为直接抑制的困难.
- 了解YAP1调节对于开发有效的癌症治疗非常重要.
研究的目的:
- 确定YAP1营业额的新兴上游监管机构.
- 研究素激酶II (CK2) 在YAP1调控中的作用.
- 阐明将CK2,DUB3和YAP1稳定性与癌症联系起来的分子机制.
主要方法:
- 高通量选用于识别YAP1监管器.
- 药理抑制 (Silmitasertib) 和基因耗尽 (CK2α) 的CK2.
- 在体外和体内研究,以评估YAP1不稳定性和瘤功能抑制.
- 对DUB3酸化的分析及其对YAP1二化的影响.
- 在卵巢癌组织中对CK2α,DUB3和YAP1表达的相关性分析.
主要成果:
- 在多种癌症类型中,CK2被确定为YAP1周转的上游调节者.
- 抑制CK2 (Silmitasertib或CK2α耗尽) 会破坏YAP1的稳定,并抑制其致癌功能.
- DUB3被确定为YAP1的二维基因酶,将CK2与YAP1的稳定性联系起来.
- 在Thr495处,CK2α直接酸化DUB3,促进YAP1的脱和稳定.
- 酸化缺陷的DUB3突变和CK2抑制损害了YAP1的稳定.
- 上调的CK2α和DUB3与卵巢癌中YAP1过度表达相关.
结论:
- CK2α-DUB3轴对YAP1稳定和YAP1驱动的瘤进展至关重要.
- 针对CK2α-DUB3轴为YAP1驱动的癌症提供了一个有前途的治疗策略.
- 这个轴代表了卵巢和其他致命癌症的潜在治疗脆弱性.
相关概念视频
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Anaphase Promoting Complex
2.8K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


